Clinical Trials
Ambroxol in Parkinson’s Disease Dementia.
Currently all of the treatments for Parkinson’s disease treat the symptoms of the disease, but do not change the long-term progression of pathology in the brain. Ambroxol is an over the counter cough medicine, with a long safety record, which is available in much of the world, but not available in Canada or the USA. We are running a phase 2 trial of Ambroxol as a disease modifying drug in Parksinson’s Disease Dementia, with the goal of slowing or stopping the progression of Parkinson’s disease Dementia. Our goal is to randomize 75 patients with Parkinson’s Disease Dementia for 1 year. Patients will be followed with cognitive testing and motor testing.
Funded by the Weston Brain Institute.
Oxytocin for empathy deficits in Frontotemporal Dementia
We are leading a phase 2 randomized controlled trial of intranasal oxytocin for social apathy and empathy deficits in Frontotemporal Dementia (FOXY) with enrollment beginning in January 2018. This study will take place at 10 academic neurology centres in Canada and the US.
Progressive Supranuclear Palsy
We are participating in the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy. Enrollment will begin in November 2018.
Sponsor: Bristol Myers Squibb
Alzheimer’s Disease
We are participating in the Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine.
Sponsor: vTv Therapeutics
